ReviewGeroScience2020
SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes.
Review in GeroScience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 318 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
318 citing papers in PubMed, 4 syntheses or guidelines pooled it, 600 citations in OpenAlex.
- Implication of the emergence of the delta (B.1.617.2) variants on vaccine effectiveness.Infection · 2022Pooled it
- Epidemiological and clinical characteristics of non-severe and severe pediatric and adult COVID-19 patients across different geographical regions in the early phase of pandemic: a systematic review and meta-analysis of observational studies.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2021Pooled it
- D-dimer levels is associated with severe COVID-19 infections: A meta-analysis.International journal of clinical practice · 2021Pooled it
- Diabetes increases the mortality of patients with COVID-19: a meta-analysis.Acta diabetologica · 2021Pooled it
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.The Lancet. Infectious diseases · 2021Trial
- Post-COVID-19 Condition Diagnosis among Older People: Findings from Swedish National Register Data.Gerontology · 2026Article
- Risk Factors and Vaccination Dose Associated with COVID-19 Mortality: A Population-Based Study in Gyeongsangbuk-do, South Korea.Pathogens (Basel, Switzerland) · 2026Article
- Key factors of the deranged antiviral response in elderly patients with COVID-19: a machine-learning analysis.GeroScience · 2026Article
- Clinical effectiveness of intensive care unit admission in older adults with COVID-19 during the first pandemic wave in Spain.BMC geriatrics · 2026Observational
- An Ecological Study on the Mortality Impact of the COVID-19 Pandemic According to Country Development Status and Pandemic Years.Epidemiologia (Basel, Switzerland) · 2026Article
- Chronic IL-21 exposure reshapes pulmonary environment, elevating risk of respiratory diseases.Cellular and molecular life sciences : CMLS · 2026Article
- Age-Related Changes in the Clinical Picture of Long COVID.Journal of the American Geriatrics Society · 2025Article
- Age and primary vaccination schedule impact humoral and cellular immunity with an inactivated SARS-CoV-2 vaccine.iScience · 2025Article
- Treatment with mitochondrial targeting antibiotics improves survival outcomes after Flock House virus infection in young and aged Drosophila melanogaster.Research square · 2025Article
- The Impact of Toll-Like Receptor 5 on Liver Function in Age-Related Metabolic Disorders.Aging cell · 2025Article
- Old hematopoietic stem cells retain competence to reconstitute a youthful B cell system that is highly responsive to protein-based vaccination.Immunity & ageing : I & A · 2025Article
- Novel biomarkers of mitochondrial dysfunction in Long COVID patients.GeroScience · 2025Article
- Paracrine FGF21 dynamically modulates mTOR signaling to regulate thymus function across the lifespan.Nature aging · 2025Article
- Article
- Creating respiratory pathogen-free environments in healthcare and nursing-care settings: a comprehensive review.GeroScience · 2025Review
258 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SARS-CoV-2 virus, the causative agent of the coronavirus infectious disease-19 (COVID-19), is taking the globe by storm, approaching 500,000 confirmed cases and over 21,000 deaths as of March 25, 2020. While under control in some affected Asian countries (Taiwan, Singapore, Vietnam), the virus demonstrated an exponential phase of infectivity in several large countries (China in late January and February and many European countries and the USA in March), with cases exploding by 30-50,000/day in the third and fourth weeks of March, 2020. SARS-CoV-2 has proven to be particularly deadly to older adults and those with certain underlying medical conditions, many of whom are of advanced age. Here, we briefly review the virus, its structure and evolution, epidemiology and pathogenesis, immunogenicity and immune, and clinical response in older adults, using available knowledge on SARS-CoV-2 and its highly pathogenic relatives MERS-CoV and SARS-CoV-1. We conclude by discussing clinical and basic science approaches to protect older adults against this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.